Physician profile
Michael E Carney
NPI 1790893287
$1,845.80
in general payments reported to CMS, 2019-2025
11 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.19 · 2020: $14.84 · 2022: $35.40 · 2023: $114 · 2024: $215 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,370 · Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,369.75 |
| Food and Beverage | $328.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,369.75 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $201.44 | 2024 | |
| Merck Sharp & Dohme LLC | $108.43 | 2019-2020 | |
| Immunogen, INC. | $72.14 | 2023 | Elahere |
| Genentech USA, INC. | $41.57 | 2023 | |
| Myriad Genetic Laboratories, INC. | $17.96 | 2022 | |
| Pfizer INC. | $17.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.47 | 2024 | |
| Clovis Oncology, INC. | $3.60 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.